precious-metals-investing LaFleur Minerals Inc. Ideally Positioned for Significant Explorer-to-Producer Transition
precious-metals-investing Growing Momentum Signals Opportunity as Explorers Shift Toward Production, Reveal Substantial Value
precious-metals-investing LaFleur Minerals Inc. Offers Meaningful Leverage to Explorer-to-Producer Inflection Point
precious-metals-investing Momentum Builds, Upside Appears as Mining Explorers Transition Toward Production, Unlock Major Hidden Value
precious-metals-investing LaFleur Minerals Advances Swanson Confirmation Drilling to Support Beacon Mill Restart and PEA
precious-metals-investing LaFleur Minerals Announces Brokered Private Placement of Gold-Linked Convertible Notes to Finance Restart of Gold Production at Beacon Gold Mill
precious-metals-investing LaFleur Minerals Provides Update on Confirmation Drilling for PEA at Swanson Gold Deposit and Beacon Gold Mill, Val-d'Or, Québec
precious-metals-investing LaFleur Minerals Closes $1.66 Million Flow-Through Offering to Advance Drilling and PEA-Related Work at its Swanson Gold Deposit
precious-metals-investing LaFleur Minerals Inc. Emerging Among Peers as Attractive, Resilient Investment Play
precious-metals-investing LaFleur Minerals Provides Update on PEA for the Restart of Beacon Gold Mill Sourcing Material from Its Swanson Gold Deposit, Val d'Or, Québec
precious-metals-investing LaFleur Minerals Announces Listing on Tradegate, Bolstering its International Visibility and Exposure to European Markets
precious-metals-investing LaFleur Minerals Announces High-Grade Gold Assay Results and Provides Update on Beacon Gold Mill and Swanson Gold Deposit Ramp-Up Activities
EMP METALS ADVANCES CONSTRUCTION OF PROJECT AURORA DEMONSTRATION PLANT BY COMPLETING INTERIOR FINISHING
FDA Accepts LEQEMBI® IQLIK Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
FDA Accepts LEQEMBI® IQLIKTM Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
Data at 2026 Boswick Burn & Wound Symposium highlight first integrated use of AVITA Medical technologies
